BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Not Recruiting

Trial ID: NCT01354431


The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

Official Title

A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion Criteria:

   - Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component

   - Previous treatment with at least one anti-angiogenic agent

   - Progressed within 6 months of study enrollment

   - Subjects should not have had more than 3 prior treatments for locally advanced or
   metastatic disease

   - Must have available tumor tissue for submission

   - Subjects must also meet various laboratory parameters for inclusion

Exclusion Criteria:

   - Subjects with any active autoimmune disease or a history of known autoimmune disease

Other protocol-defined inclusion/exclusion criteria apply


biological: nivolumab

biological: nivolumab

biological: nivolumab

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts